Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily pretreated relapsed/refractory patient population support continued development of NX-2127 in non-Hodgkin lymphoma (NHL) Nurix will webcast a Key Opinion Leader (KOL) event at 8:30 p.m.

积极的初步疗效数据和良好的安全性支持计划在慢性淋巴细胞白血病（CLL）中广泛开发NX-5948，在经过严重预处理的复发/难治性患者人群中快速持久的完全反应支持NX-2127在非霍奇金淋巴瘤（NHL）中的持续发展Nurix将于晚上8:30在线直播关键意见领袖（KOL）事件。

PT today to review data presented at the ASH meeting from its BTK degrader portfolio SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented positive clinical data from its orally available degraders of BTK, NX-5948 and NX-2127, which are being evaluated in separate Phase 1a/1b clinical trials in patients with relapsed or refractory (r/r) B-cell malignancies, including CLL, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), primary CNS lymphoma (PCNS), and Waldenström’s macroglobulinemia (WM).

PT今天回顾了其BTK降解剂组合在ASH会议上提交的数据，旧金山，2023年12月11日（环球通讯社）--Nurix Therapeutics，Inc.（纳斯达克：NRIX），一家临床阶段的生物制药公司，开发旨在治疗血液恶性肿瘤和实体瘤患者的靶向蛋白质调节药物，今天提供了BTK，NX-5948和NX-2127口服降解物的阳性临床数据，这些数据正在复发或难治性（r/r）B细胞恶性肿瘤患者的1a/1b期临床试验中进行评估，包括CLL，套细胞淋巴瘤（MCL），弥漫性大B细胞淋巴瘤（DLBCL），边缘区淋巴瘤（MZL），滤泡性淋巴瘤（FL），原发性中枢神经系统淋巴瘤（PCNS）和Waldenström巨球蛋白血症（WM）。

These data were presented in two posters at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in San Diego, California. “Targeting BTK is an established treatment paradigm for patients with CLL and other B-cell malignancies. BTK degraders represent a novel next generation therapy for these patients,” said Alexey Danilov, M.D., Ph.D.

这些数据在加利福尼亚州圣地亚哥举行的第65届美国血液学会（ASH）年会和博览会上以两张海报呈现。医学博士Alexey Danilov说：“针对BTK是CLL和其他B细胞恶性肿瘤患者的既定治疗模式。BTK降解剂代表了这些患者的新一代治疗方法。”。

Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope National Medical Center and an investigator on both studies. “CLL patients whose disease progresses on or after treatment with BTK inhibitors, most often due to the development of.

希望之城国家医学中心托尼·斯蒂芬森淋巴瘤中心教授兼联合主任，两项研究的研究员。“在使用BTK抑制剂治疗时或治疗后疾病进展的CLL患者，通常是由于发展。